These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23295789)

  • 1. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
    Zucca E; Conconi A; Laszlo D; López-Guillermo A; Bouabdallah R; Coiffier B; Sebban C; Jardin F; Vitolo U; Morschhauser F; Pileri SA; Copie-Bergman C; Campo E; Jack A; Floriani I; Johnson P; Martelli M; Cavalli F; Martinelli G; Thieblemont C
    J Clin Oncol; 2013 Feb; 31(5):565-72. PubMed ID: 23295789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
    Zucca E; Conconi A; Martinelli G; Bouabdallah R; Tucci A; Vitolo U; Martelli M; Pettengell R; Salles G; Sebban C; Guillermo AL; Pinotti G; Devizzi L; Morschhauser F; Tilly H; Torri V; Hohaus S; Ferreri AJM; Zachée P; Bosly A; Haioun C; Stelitano C; Bellei M; Ponzoni M; Moreau A; Jack A; Campo E; Mazzucchelli L; Cavalli F; Johnson P; Thieblemont C
    J Clin Oncol; 2017 Jun; 35(17):1905-1912. PubMed ID: 28355112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
    Stathis A; Pirosa MC; Orsucci L; Feugier P; Tani M; Ghesquières H; Musuraca G; Rossi FG; Merli F; Guièze R; Gyan E; Gini G; Marino D; Gressin R; Morschhauser F; Cavallo F; Palombi F; Conconi A; Tessoulin B; Tilly H; Zanni M; Cabras MG; Capochiani E; Califano C; Celli M; Pulsoni A; Angrilli F; Occhini U; Casasnovas RO; Cartron G; Devizzi L; Haioun C; Liberati AM; Houot R; Merli M; Pietrantuono G; Re F; Spina M; Landi F; Cavalli F; Bertoni F; Rossi D; Ielmini N; Borgo E; Luminari S; Zucca E; Thieblemont C
    Haematologica; 2024 Aug; 109(8):2564-2573. PubMed ID: 38385243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
    Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
    Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen.
    Sachanas S; Pangalis GA; Vassilakopoulos TP; Korkolopoulou P; Kontopidou FN; Athanasoulia M; Yiakoumis X; Kalpadakis C; Georgiou G; Masouridis S; Moschogiannis M; Tsirkinidis P; Pappis V; Kokoris SI; Siakantaris MP; Panayiotidis P; Angelopoulou MK
    Leuk Lymphoma; 2011 Mar; 52(3):387-93. PubMed ID: 21133713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study.
    Amiot A; Lévy M; Copie-Bergman C; Dupuis J; Szablewski V; Le Baleur Y; Baia M; Belhadj K; Sobhani I; Leroy K; Haioun C; Delchier JC
    Aliment Pharmacol Ther; 2014 Mar; 39(6):619-28. PubMed ID: 24467480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
    Herold M; Haas A; Srock S; Neser S; Al-Ali KH; Neubauer A; Dölken G; Naumann R; Knauf W; Freund M; Rohrberg R; Höffken K; Franke A; Ittel T; Kettner E; Haak U; Mey U; Klinkenstein C; Assmann M; von Grünhagen U;
    J Clin Oncol; 2007 May; 25(15):1986-92. PubMed ID: 17420513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP).
    Wöhrer S; Drach J; Hejna M; Scheithauer W; Dirisamer A; Püspök A; Chott A; Raderer M
    Ann Oncol; 2003 Dec; 14(12):1758-61. PubMed ID: 14630681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.
    Troch M; Kiesewetter B; Willenbacher W; Willenbacher E; Zebisch A; Linkesch W; Fridrik M; Müllauer L; Greil R; Raderer M
    Haematologica; 2013 Feb; 98(2):264-8. PubMed ID: 22983582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study.
    Lévy M; Dupuis J; Charpy C; Martin A; Itti E; Sobhani I; Haioun C; Amiot A
    Leuk Lymphoma; 2022 Nov; 63(11):2597-2603. PubMed ID: 35687839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study.
    Lévy M; Copie-Bergman C; Amiot A; Dupuis J; Le Baleur Y; Belhadj K; Hémery F; Sobhani I; Delfau-Larue MH; Leroy K; Haioun C; Delchier JC
    Leuk Lymphoma; 2013 May; 54(5):940-4. PubMed ID: 22978684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
    Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
    J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up.
    Lévy M; Copie-Bergman C; Molinier-Frenkel V; Riou A; Haioun C; Gaulard P; Delfau-Larue MH; Sobhani I; Leroy K; Delchier JC
    Leuk Lymphoma; 2010 Feb; 51(2):284-90. PubMed ID: 20038225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
    Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
    Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
    Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database.
    Olszewski AJ; Castillo JJ
    Ann Oncol; 2013 May; 24(5):1352-9. PubMed ID: 23348804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
    Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
    Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
    Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
    Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
    Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.
    Hillmen P; Gribben JG; Follows GA; Milligan D; Sayala HA; Moreton P; Oscier DG; Dearden CE; Kennedy DB; Pettitt AR; Nathwani A; Varghese A; Cohen D; Rawstron A; Oertel S; Pocock CF
    J Clin Oncol; 2014 Apr; 32(12):1236-41. PubMed ID: 24638012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.